DS3610 / Daiichi Sankyo - LARVOL DELTA

A Study of DS3610a in Participants With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Solid Tumor

DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo (Businesswire) - "The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors."

First-in-human • P1 data • Solid Tumor

DS-3610: Initiation of P1 trial (NCT07159126) for solid tumors in H2 FY2025 (Daiichi Sankyo) - Q2 FY2025 Results

Trial initiation date • Oncology • Solid Tumor

A Study of DS3610a in Participants With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Daiichi Sankyo

New P1 trial • Solid Tumor